Treatment of Skin Disease E-Book
by Mark G. Lebwohl
2020-07-25 11:39:46
Treatment of Skin Disease E-Book
by Mark G. Lebwohl
2020-07-25 11:39:46
Covering more than 250 of the most common dermatologic conditions from A to Z, Treatment of Skin Disease, 5th Edition, by Drs. Mark G. Lebwohl, Warren R. Heymann, John Berth-Jones, and Ian Coulson, is your go-to resource for authoritative, evidence-b...
Read more
Covering more than 250 of the most common dermatologic conditions from A to Z, Treatment of Skin Disease, 5th Edition, by Drs. Mark G. Lebwohl, Warren R. Heymann, John Berth-Jones, and Ian Coulson, is your go-to resource for authoritative, evidence-based treatment strategies in your daily practice. This award-winning text provides guidance on the fast-moving dermatological therapy options for virtually any skin disease youâre likely to encounter, including third-line and unusual therapies when initial options have not been successful. Summaries of each treatment strategy are accompanied by detailed discussions of treatment choices, with ratings on a consistent scale ranging from clinical studies to anecdotal reports. Puts every possible therapeutic option at your disposal â including management strategies and first- to third-line therapies â for a truly complete guide to the vast array of dermatologic treatment options. Presents information in a consistent, tabular format, with checklists of diagnostic and investigative pearls and color-coded boxes for quick reference. Offers the combined knowledge and expertise of the worldâs leading authorities in dermatology. Features eight all-new chapters on Atypical Fibroxanthoma, Confluent and Reticulated Papillomatosis, Cryopyrin Associated Periodic Syndromes (CAPS), Hypopigmented Dermatoses, Nail Psoriasis, Necrolytic Acral Erythema, Post-inflammatory Hyperpigmentation, and Regional Pain. Provides more than 250 full-color clinical images of skin diseases, most of which are new to this edition. Includes off-label uses, new treatments like therapeutic antibodies and hedgehog inhibitors, and new indications for existing treatments.
Less
